Key Takeaways
- • Wynnchurch Capital has agreed to sell FloWorks, an industrial flow control distributor, to Ferguson Enterprises in a cash transaction valued at approximately $1.6 billion, representing a significant exit for the private equity firm.
- • Archimed has completed its take-private acquisition of Esperion, a biopharmaceutical company, in a transaction valued at $1.1 billion, marking the closure of a healthcare-focused deal in the alternative investment space.
- • Both transactions reflect continued private equity and alternative investment activity in industrial distribution and life sciences sectors during the current market environment.
Summary
Wynnchurch Capital has reached an agreement to sell FloWorks, a distributor specializing in industrial flow control products, to Ferguson Enterprises in an all-cash transaction. The deal is valued at approximately $1.6 billion and represents a substantial exit opportunity for Wynnchurch from its investment in the flow control distribution business. FloWorks operates within the industrial services and distribution sector, serving customers across multiple verticals requiring fluid handling and flow management solutions.
In parallel, Archimed has completed its previously announced take-private transaction of Esperion, a biopharmaceutical company. The transaction closed at a valuation of approximately $1.1 billion in cash consideration. This acquisition represents Archimed's investment activity in the healthcare and life sciences sectors, where it pursues consolidation and platform-building strategies typical of alternative asset managers with healthcare-focused mandates.
Both transactions illustrate ongoing dealmaking momentum in mid-market private equity and alternative investment, particularly in industrial distribution and specialty healthcare sectors. The FloWorks sale to Ferguson Enterprises, a major player in the building and industrial supplies distribution space, suggests continued strategic appetite among large distributors for bolt-on acquisitions that expand product offerings and market reach. The Esperion take-private by Archimed reflects healthcare investors' interest in acquiring public companies at attractive valuations and repositioning them under alternative investment ownership structures.
These deals underscore sustained liquidity in the alternative investment market and the continued viability of exit strategies through both strategic sales and take-private transactions during 2026.
In parallel, Archimed has completed its previously announced take-private transaction of Esperion, a biopharmaceutical company. The transaction closed at a valuation of approximately $1.1 billion in cash consideration. This acquisition represents Archimed's investment activity in the healthcare and life sciences sectors, where it pursues consolidation and platform-building strategies typical of alternative asset managers with healthcare-focused mandates.
Both transactions illustrate ongoing dealmaking momentum in mid-market private equity and alternative investment, particularly in industrial distribution and specialty healthcare sectors. The FloWorks sale to Ferguson Enterprises, a major player in the building and industrial supplies distribution space, suggests continued strategic appetite among large distributors for bolt-on acquisitions that expand product offerings and market reach. The Esperion take-private by Archimed reflects healthcare investors' interest in acquiring public companies at attractive valuations and repositioning them under alternative investment ownership structures.
These deals underscore sustained liquidity in the alternative investment market and the continued viability of exit strategies through both strategic sales and take-private transactions during 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.